Feldmann Robert E, Kranz Gottfried, Praschak-Rieder Nicole, Kasper Siegfried
Department of Physiology and Pathophysiology, Division of Systems Physiology, University of Heidelberg Medical Center, Heidelberg, Germany.
Curr Med Res Opin. 2009 Sep;25(9):2281-5. doi: 10.1185/03007990903116172.
The authors report the case of a 32-year-old man who had been treated for anxiety and obsessive-compulsive disorder and had received 800 mg methylphenobarbital (MPB). After switching to a barbiturate-free schedule, his condition continued to be unstable for more than 21 MPB half-lives (approx. 30 days) and did not stabilize until MPB-metabolites dropped below their urinary detection limit. Considering that this article provides findings from a single patient, the authors use this experience to discuss and emphasize the importance of clinical control of barbiturates in psychiatry.
作者报告了一例32岁男性病例，该患者曾接受焦虑症和强迫症治疗，并服用过800毫克甲基苯巴比妥（MPB）。在改用无巴比妥酸盐治疗方案后，他的病情在超过21个MPB半衰期（约30天）的时间里持续不稳定，直到MPB代谢物降至尿液检测限以下才趋于稳定。鉴于本文提供的是单个患者的研究结果，作者利用这一经验来讨论并强调在精神病学中对巴比妥酸盐进行临床管控的重要性。
